drugset / Trial / NCT00604656

Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes

NCT00604656

Phase 3 Completed 241 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin aspart produced by current process compared to that of insulin aspart produced by NN2000 process in subjects with type 2 diabetes.

Timeline

Start
2003-05-05
Primary completion
2004-01-29
Completion
2004-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic